The aim of this company is to explore the mechanism of SLC-associated immunometabolism, lysosomal function, and mucosal defense and develop drugs for immuno-oncology, inflammatory disorders, and neurological diseases. The gene discussed is CCL21; the disease is nervous system disorder.